PIK3CA and neoplasm: However, significant disparity between clinical and preclinical data, and heterogeneity in objective response rates implied that a more complicated interaction network in the tumour immune microenvironment (TIME) might be involved in regulating the clinical efficacy of PI3K inhibitor‐based target therapies.6, 7, 8